These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study. Hatz K; Prünte C Acta Ophthalmol; 2017 Feb; 95(1):e67-e72. PubMed ID: 27009503 [TBL] [Abstract][Full Text] [Related]
23. Comparison of Strategies of Treatment with Ranibizumab in Newly-Diagnosed Cases of Neovascular Age-Related Macular Degeneration. Garweg JG; Niderprim SA; Russ HM; Pfister IB J Ocul Pharmacol Ther; 2017 Dec; 33(10):773-778. PubMed ID: 28953427 [TBL] [Abstract][Full Text] [Related]
24. Canadian preference and trends survey results for anti-VEGF treatment of macular edema. Rayat JS; Grewal PS; Whelan J; Tennant MT; Choudhry N Can J Ophthalmol; 2016 Jun; 51(3):233-7. PubMed ID: 27316276 [No Abstract] [Full Text] [Related]
25. Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema: A Systematic Review and Meta-analysis. Avery RL; Gordon GM JAMA Ophthalmol; 2016 Jan; 134(1):21-9. PubMed ID: 26513684 [TBL] [Abstract][Full Text] [Related]
26. Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab. Konidaris V; Al-Hubeshy Z; Tsaousis KT; Gorgoli K; Banerjee S; Empeslidis T Int Ophthalmol; 2018 Feb; 38(1):207-213. PubMed ID: 28405787 [TBL] [Abstract][Full Text] [Related]
27. Long-Term Anatomical and Functional Outcomes in Patients with Ischemic Central Retinal Vein Occlusion Treated with Anti-Vascular Endothelial Growth Factor Agents. Chatziralli I; Theodossiadis G; Parikakis E; Mitropoulos PG; Theodossiadis P Ophthalmic Res; 2017; 58(4):203-208. PubMed ID: 28427057 [TBL] [Abstract][Full Text] [Related]
28. Changes in flare after intravitreal injection of three different anti-vascular endothelial growth factor medications. Blaha GR; Brooks NO; Mackel CE; Pani A; Stewart AP; Price LL; Barouch FC; Chang J; Marx JL Retina; 2015 Mar; 35(3):577-81. PubMed ID: 25158942 [TBL] [Abstract][Full Text] [Related]
29. Effect of intravitreal anti-VEGF on choroidal thickness in patients with diabetic macular edema using spectral domain OCT. Kniggendorf VF; Novais EA; Kniggendorf SL; Xavier C; Cole ED; Regatieri CV Arq Bras Oftalmol; 2016; 79(3):155-8. PubMed ID: 27463625 [TBL] [Abstract][Full Text] [Related]
30. Predictors of Outcome in Patients with Neovascular Age-Related Macular Degeneration Switched from Ranibizumab to 8-Weekly Aflibercept. Chatziralli I; Nicholson L; Vrizidou E; Koutsiouki C; Menon D; Sergentanis TN; Citu MC; Hamilton R; Patel PJ; Hykin P; Sivaprasad S Ophthalmology; 2016 Aug; 123(8):1762-1770. PubMed ID: 27289179 [TBL] [Abstract][Full Text] [Related]
31. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion. Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794 [TBL] [Abstract][Full Text] [Related]
32. Scheduled versus Pro Re Nata Dosing in the VIEW Trials. Richard G; Monés J; Wolf S; Korobelnik JF; Guymer R; Goldstein M; Norenberg C; Sandbrink R; Zeitz O Ophthalmology; 2015 Dec; 122(12):2497-503. PubMed ID: 26477840 [TBL] [Abstract][Full Text] [Related]
33. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis. Ba J; Peng RS; Xu D; Li YH; Shi H; Wang Q; Yu J Drug Des Devel Ther; 2015; 9():5397-405. PubMed ID: 26451092 [TBL] [Abstract][Full Text] [Related]
34. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Brown DM; Heier JS; Clark WL; Boyer DS; Vitti R; Berliner AJ; Zeitz O; Sandbrink R; Zhu X; Haller JA Am J Ophthalmol; 2013 Mar; 155(3):429-437.e7. PubMed ID: 23218699 [TBL] [Abstract][Full Text] [Related]
35. Long-term effect of anti-vascular endothelial growth factor injections on intraocular pressure. Nariani A; Williams B; Hariprasad SM Indian J Ophthalmol; 2016 Sep; 64(9):643-647. PubMed ID: 27853011 [TBL] [Abstract][Full Text] [Related]
36. Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration. Barthelmes D; Campain A; Nguyen P; Arnold JJ; McAllister IL; Simpson JM; Hunyor AP; Guymer R; Essex RW; Morlet N; Gillies MC; Br J Ophthalmol; 2016 Dec; 100(12):1640-1645. PubMed ID: 26994110 [TBL] [Abstract][Full Text] [Related]
37. Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis. Sangroongruangsri S; Ratanapakorn T; Wu O; Anothaisintawee T; Chaikledkaew U Expert Rev Clin Pharmacol; 2018 Sep; 11(9):903-916. PubMed ID: 30071180 [TBL] [Abstract][Full Text] [Related]
38. Switching Anti-VEGF Drugs in the Treatment of Diabetic Macular Edema. Banaee T; Ashraf M; Conti FF; Singh RP Ophthalmic Surg Lasers Imaging Retina; 2017 Sep; 48(9):748-754. PubMed ID: 28902336 [TBL] [Abstract][Full Text] [Related]
39. Disorganization of the Retinal Inner Layers after Anti-VEGF Treatment for Macular Edema due to Branch Retinal Vein Occlusion. Nakano E; Ota T; Jingami Y; Nakata I; Hayashi H; Yamashiro K Ophthalmologica; 2018; 240(4):229-234. PubMed ID: 30089307 [TBL] [Abstract][Full Text] [Related]
40. Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases. Ou WC; Brown DM; Payne JF; Wykoff CC Am J Ophthalmol; 2017 Aug; 180():8-17. PubMed ID: 28549848 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]